clinical trial · NCT06659263
RE104 Clinical Lactation Study
LactationRE104 for Injection
brief summary
The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.
started
Nov 13, 2024
primary completion
May 28, 2025
completion
Jun 4, 2025
last updated
Jun 12, 2025
official title
A Phase 1, Open-label, Single Dose Study to Evaluate the Concentration of RE104 and Its Major Metabolites in Breast Milk and Plasma of Healthy Lactating Women.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol